Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ariana raises venture funds for decision tool

This article was originally published in Scrip

Executive Summary

Ariana Pharma has raised its first round of venture financing, €1.5 million from Vizille Capital Innovation. VCI will take a minority stake in the decision tool developer alongside existing shareholders, Institut Pasteur and company management. Ariana, which has been mainly self-funding until now, has established a growing software business through collaboration and licensing agreements with pharmaceutical companies, such as Pfizer, GlaxoSmithKline, Novartis and Lundbeck. Its lead product is KEM (Knowledge Extraction and Management), a data mining tool. The new funding will be used to strengthen the company's sales and marketing infrastructure, and for further development work to add functionality to KEM that will enhance its use in clinical trials and drug safety domains. Ariana was founded in 2003 and is headquartered in Paris, France.

You may also be interested in...

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts